- Home
- |
- Contact
- |
- Pharmacovigilance
- |
Welcome to
Chiesi group
The first extra-fine dry powder inhaler was successfully launched in Italy on October 2013 to address the unmet doctors’ and patients’ need of a user-friendly and safe drug delivery device. Being an high quality alternative to the pressurised metered dose inhaler, this innovative device can deliver extra-fine particles of the fixed beclomethasone-formoterol combination for the treatment of chronic bronchial asthma.
The extra-fine formulation contains particles of dimension that allow the targeting of the small airways, with a significantly increased drug deposition and, therefore, a better therapeutic effectiveness and an enhanced control of asthma. In turn, a better control of the disease has a positive impact on the quality of life of the patients, determining also benefits on direct and indirect social and healthcare costs.
Thanks to its ease of use and its drug delivery safety, this new dry powder inhaler can increase the patient compliance to regular treatment, allowing also an immediate control of the correct drug intake.
